Skip to content
Subscriber Only

Celgene Pins Future on Decoding Successful Cancer Treatment

  • Drugmaker hopes its grasp of Revlimid will result in more hits
  • Thalidomide, infamous for birth defects, gets another chance
Photographer: Martin Leissl/Bloomberg
Updated on

Thalidomide was infamous for causing birth defects when Celgene Corp. transformed it into a blood-cancer treatment that brings in $7 billion a year.

Trouble was, Celgene didn’t know exactly how the drug, Revlimid, worked.